Correction: Getinge announces preliminary results for third quarter 2013
Getinge’s consolidated profit before tax for the third quarter 2013 is expected to amount to 560-570 MSEK, which materially deviates from the expectations indicated by the market consensus estimate.
The weaker earnings statement is primarily attributable to the following factors:
- unfavorable product mix within the Critical Care division
- time delay in cost synergies related to the TSS acquisition
- the US Medical Device Tax and negative exchange-rate effects
For the full year, the organic volume growth is still expected to exceed last year and amount to approximately 3-4 %. Profit before tax for the full year is estimated to total at 3 000 – 3 200 MSEK including restructuring expenses and other nonrecurring expenses.
This announcement will be followed by a conference call at 10.00 AM CET today, hosted by Johan Malmquist, CEO Getinge Group and Ulf Grunander, CFO Getinge Group.
Getinge will issue its full Q3 report for 2013 on October 15th at 1:00 PM CET.
To participate, please call:
Sweden: +46 (0)8 5065 3938
UK: +44 (0)20 3427 1905
09.45 Call the conference number
11.00 End of conference
A recorded version of the conference will be accessible for five working days at the following number:
Sweden: +46 (0)8 5051 3897
UK: +44 (0)20 3427 0598
US: +1 347 366 9565
For further information, please contact:
Johan Malmquist Ulf Grunander
CEO, Getinge Group CFO, Getinge Group
Phone: +46 10 335 55 33 Phone: +46 10 335 55 80
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.